0001209191-22-059938.txt : 20221206
0001209191-22-059938.hdr.sgml : 20221206
20221206085050
ACCESSION NUMBER: 0001209191-22-059938
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221201
FILED AS OF DATE: 20221206
DATE AS OF CHANGE: 20221206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lochner Daniel
CENTRAL INDEX KEY: 0001791187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 221446767
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 106
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 106
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-01
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001791187
Lochner Daniel
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 106
PRINCETON
NJ
08540
0
1
0
0
Chief Financial Officer
Common Stock
2022-12-01
4
F
0
3258
11.20
D
74463
D
The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units (the "RSUs"). Such RSUs were previously reported on the Reporting Person's Form 4 as to (i) 11,222 filed with the Securities and Exchange Commission on February 2, 2021 (the "2021 Award"); and (ii) 19,500 filed with the Securities and Exchange Commission on January 11, 2022 (the "2022 Award"). 2,805 RSUs of the 2021 Award and 4,875 RSUs of the 2022 Award were subsequently accelerated, effective December 1, 2022, resulting in the withholding being reported herein.
/s/ Brandon Fenn, Attorney-in-Fact
2022-12-06